Cargando…

PRES in the course of hemato-oncological treatment in children

INTRODUCTION: Posterior reversible leukoencephalopathy syndrome (PRES) is a clinical syndrome of varying aetiologies, characterised by acute neurological symptoms of brain dysfunction with MRI abnormalities in posterior cerebral white and grey matter. In most cases, symptoms resolve without neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Musioł, Katarzyna, Waz, Sylwia, Boroń, Michał, Kwiatek, Magdalena, Machnikowska-Sokołowska, Magdalena, Gruszczyńska, Katarzyna, Sobol-Milejska, Grażyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856901/
https://www.ncbi.nlm.nih.gov/pubmed/29198072
http://dx.doi.org/10.1007/s00381-017-3664-y
_version_ 1783307366094077952
author Musioł, Katarzyna
Waz, Sylwia
Boroń, Michał
Kwiatek, Magdalena
Machnikowska-Sokołowska, Magdalena
Gruszczyńska, Katarzyna
Sobol-Milejska, Grażyna
author_facet Musioł, Katarzyna
Waz, Sylwia
Boroń, Michał
Kwiatek, Magdalena
Machnikowska-Sokołowska, Magdalena
Gruszczyńska, Katarzyna
Sobol-Milejska, Grażyna
author_sort Musioł, Katarzyna
collection PubMed
description INTRODUCTION: Posterior reversible leukoencephalopathy syndrome (PRES) is a clinical syndrome of varying aetiologies, characterised by acute neurological symptoms of brain dysfunction with MRI abnormalities in posterior cerebral white and grey matter. In most cases, symptoms resolve without neurological consequences. AIM: The aim of this paper is the analysis of predisposing factors, clinical outcomes and radiological features of PRES in eight children with hemato-oncological disease. MATERIAL AND METHODS: We analysed the medical records of eight hemato-oncological patients aged from 3.0 to 16.1 years. The mean of age at primary diagnosis was 8.5 years. RESULTS: All patients had both clinical and radiological PRES features. Seven out of eight underwent intensive chemotherapy regimens. Time elapsed from start of treatment to the occurrence of PRES ranged from 6 to 556 days. In one case, PRES occurred before chemotherapy and was the first symptom of cancer. Most (six of eight) patients had history of hypertension (> 95pc) and some (two of eight) occurred electrolyte imbalance—mainly hypomagnesaemia. Patients presented headache (seven of eight), disturbances of consciousness (six of eight), seizures (six of eight), visual changes (four of eight) and vomiting (three of eight). MRI demonstrated abnormalities in seven children: typical cerebral oedema in the white matter of the occipital to the parietal lobes. Most patient lesions in the MRI shrunk after 4 weeks, and clinical symptoms of PRES disappeared completely within a few hours to few days. CONCLUSION: PRES may complicate oncological treatment in children. Hypertension is the most important risk factor of PRES. PRES should be included in differential diagnosis in all patients with acute neurological symptoms.
format Online
Article
Text
id pubmed-5856901
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58569012018-03-21 PRES in the course of hemato-oncological treatment in children Musioł, Katarzyna Waz, Sylwia Boroń, Michał Kwiatek, Magdalena Machnikowska-Sokołowska, Magdalena Gruszczyńska, Katarzyna Sobol-Milejska, Grażyna Childs Nerv Syst Original Paper INTRODUCTION: Posterior reversible leukoencephalopathy syndrome (PRES) is a clinical syndrome of varying aetiologies, characterised by acute neurological symptoms of brain dysfunction with MRI abnormalities in posterior cerebral white and grey matter. In most cases, symptoms resolve without neurological consequences. AIM: The aim of this paper is the analysis of predisposing factors, clinical outcomes and radiological features of PRES in eight children with hemato-oncological disease. MATERIAL AND METHODS: We analysed the medical records of eight hemato-oncological patients aged from 3.0 to 16.1 years. The mean of age at primary diagnosis was 8.5 years. RESULTS: All patients had both clinical and radiological PRES features. Seven out of eight underwent intensive chemotherapy regimens. Time elapsed from start of treatment to the occurrence of PRES ranged from 6 to 556 days. In one case, PRES occurred before chemotherapy and was the first symptom of cancer. Most (six of eight) patients had history of hypertension (> 95pc) and some (two of eight) occurred electrolyte imbalance—mainly hypomagnesaemia. Patients presented headache (seven of eight), disturbances of consciousness (six of eight), seizures (six of eight), visual changes (four of eight) and vomiting (three of eight). MRI demonstrated abnormalities in seven children: typical cerebral oedema in the white matter of the occipital to the parietal lobes. Most patient lesions in the MRI shrunk after 4 weeks, and clinical symptoms of PRES disappeared completely within a few hours to few days. CONCLUSION: PRES may complicate oncological treatment in children. Hypertension is the most important risk factor of PRES. PRES should be included in differential diagnosis in all patients with acute neurological symptoms. Springer Berlin Heidelberg 2017-12-02 2018 /pmc/articles/PMC5856901/ /pubmed/29198072 http://dx.doi.org/10.1007/s00381-017-3664-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Musioł, Katarzyna
Waz, Sylwia
Boroń, Michał
Kwiatek, Magdalena
Machnikowska-Sokołowska, Magdalena
Gruszczyńska, Katarzyna
Sobol-Milejska, Grażyna
PRES in the course of hemato-oncological treatment in children
title PRES in the course of hemato-oncological treatment in children
title_full PRES in the course of hemato-oncological treatment in children
title_fullStr PRES in the course of hemato-oncological treatment in children
title_full_unstemmed PRES in the course of hemato-oncological treatment in children
title_short PRES in the course of hemato-oncological treatment in children
title_sort pres in the course of hemato-oncological treatment in children
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856901/
https://www.ncbi.nlm.nih.gov/pubmed/29198072
http://dx.doi.org/10.1007/s00381-017-3664-y
work_keys_str_mv AT musiołkatarzyna presinthecourseofhematooncologicaltreatmentinchildren
AT wazsylwia presinthecourseofhematooncologicaltreatmentinchildren
AT boronmichał presinthecourseofhematooncologicaltreatmentinchildren
AT kwiatekmagdalena presinthecourseofhematooncologicaltreatmentinchildren
AT machnikowskasokołowskamagdalena presinthecourseofhematooncologicaltreatmentinchildren
AT gruszczynskakatarzyna presinthecourseofhematooncologicaltreatmentinchildren
AT sobolmilejskagrazyna presinthecourseofhematooncologicaltreatmentinchildren